150 related articles for article (PubMed ID: 2683316)
1. Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guerin.
Peuchmaur M; Benoit G; Vieillefond A; Chevalier A; Lemaigre G; Martin ED; Jardin A
Urol Res; 1989; 17(5):299-303. PubMed ID: 2683316
[TBL] [Abstract][Full Text] [Related]
2. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
[TBL] [Abstract][Full Text] [Related]
3. Class I and class II HLA antigen expression by transitional cell carcinoma of the bladder: correlation with T-cell infiltration and BCG treatment.
Stefanini GF; Bercovich E; Mazzeo V; Grigioni WF; Emili E; D'Errico A; Lo Cigno M; Tamagnini N; Mazzetti M
J Urol; 1989 Jun; 141(6):1449-53. PubMed ID: 2657113
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma.
Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG
Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin-treated superficial bladder cancer: correlation of morphology with immunophenotyping.
Leong AS; Wannakrairot P; Jose J; Milios J
J Pathol; 1990 Sep; 162(1):35-41. PubMed ID: 2231190
[TBL] [Abstract][Full Text] [Related]
6. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
[TBL] [Abstract][Full Text] [Related]
7. [Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder tumors: effect of intravesical BCG on papillary tumors].
Hagiwara M; Asano T; Iigaya T; Tsukamoto T; Nishida K
Nihon Hinyokika Gakkai Zasshi; 1986 Oct; 77(10):1623-30. PubMed ID: 3820900
[No Abstract] [Full Text] [Related]
8. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
9. [Severely contracted bladder following intravesical bacillus Calmette-Guérin therapy].
Yoshimura K; Saiki S; Kuroda M; Kiyohara H; Kotake T
Nihon Hinyokika Gakkai Zasshi; 1988 Nov; 79(11):1848-51. PubMed ID: 3216568
[No Abstract] [Full Text] [Related]
10. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin.
Hillyard RW; Ladaga L; Schellhammer PF
J Urol; 1988 Feb; 139(2):290-3. PubMed ID: 3339727
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
12. Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
Böhle A; Busemann E; Gerdes J; Ulmer AJ; Flad HD; Jocham D
Dev Biol Stand; 1992; 77():199-209. PubMed ID: 1426663
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.
Patard JJ; Chopin DK; Boccon-Gibod L
World J Urol; 1993; 11(3):165-8. PubMed ID: 8401636
[TBL] [Abstract][Full Text] [Related]
14. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
Witjes JA; vd Meijden AP; Debruyne FM
Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.
Böhle A; Thanhäuser A; Ulmer AJ; Ernst M; Flad HD; Jocham D
J Urol; 1993 Dec; 150(6):1932-7. PubMed ID: 8230540
[TBL] [Abstract][Full Text] [Related]
16. ABO(H) antigens and beta-2 microglobulin in transitional cell carcinoma. Predictors of response to intravesical bacillus Calmette-Guerin.
Sanders H; McCue P; Graham SD
Cancer; 1991 Jun; 67(12):3024-8. PubMed ID: 1710534
[TBL] [Abstract][Full Text] [Related]
17. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
Rintala E; Jauhiainen K; Alfthan O; Hansson E; Juusela H; Kanerva K; Korhonen H; Permi J; Sotarauta M; Vaalasti T
Eur Urol; 1991; 20(1):19-25. PubMed ID: 1743226
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guérin treatment of 39 patients with superficial transitional cell carcinoma of the bladder.
al Khalifa MA; Elfving P; Månsson W; Colleen S
Scand J Urol Nephrol; 1991; 25(2):135-9. PubMed ID: 1871559
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical markers defined by monoclonal antibodies and response to bacillus Calmette-Guérin endovesical immunotherapy for superficial bladder tumors.
Flam TA; Chopin DK; Leleu C; Abbou CC; Steg A; Deslignères S; Boccon-Gibod L
Eur Urol; 1990; 17(4):338-42. PubMed ID: 1694766
[TBL] [Abstract][Full Text] [Related]
20. Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer.
Lage JM; Bauer WC; Kelley DR; Ratliff TL; Catalona WJ
J Urol; 1986 May; 135(5):916-9. PubMed ID: 3959240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
